Hepatitis A vaccine immunogenicity among seronegative liver transplanted children.
Children
Hepatitis A virus
Immunity
Liver transplant
Vaccine immunogenicity
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 Sep 2024
27 Sep 2024
Historique:
received:
03
02
2024
accepted:
17
09
2024
medline:
28
9
2024
pubmed:
28
9
2024
entrez:
28
9
2024
Statut:
epublish
Résumé
The hepatitis A virus (HAV) vaccine is highly immunogenic in general, yet data on its use in liver-transplanted (LT) children is limited. This study aimed to determine the seroimmunity to HAV in all LT children, and the immunogenicity of an inactivated HAV vaccine in seronegative LT children at King Chulalongkorn Memorial Hospital. Seronegative LT children received the inactivated HAV vaccine at 0 and 6-8 months with adverse events monitored for 3 days post-immunization. The result reviewed that among 105 LT children, vaccination records were available for 81%, of which 7.1% and 16.5% with one and two doses of HAV vaccine were immunized before transplantation, respectively. Post-transplantation, 20.1% were seropositive for HAV, with 9.5% due to pre-transplant immunization. Eighty-three seronegative LT children (aged 7.25 ± 4.40 years; 48.6% male) received two vaccine doses. The seropositive rate increased following the first and second doses and reached to 51.5%, and 92.9%, respectively (p < 0.001), with no serious adverse events reported. Age at vaccination and the interval from transplantation to vaccination were risk factors for non-responsiveness (p < 0.001). The study highlighted inadequate HAV vaccination coverage, leaving most LT children susceptible to infection. HAV vaccine proved highly immunogenic and safe, emphasizing the need for improved vaccination strategies before and after liver transplantation.Trial registration TCTR20220110001.
Identifiants
pubmed: 39333725
doi: 10.1038/s41598-024-73390-z
pii: 10.1038/s41598-024-73390-z
doi:
Substances chimiques
Hepatitis A Vaccines
0
Hepatitis A Antibodies
0
Vaccines, Inactivated
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
22202Subventions
Organisme : the Ratchadapiseksompotch Fund Chulalongkorn University
ID : Grant Number RCU_H_64_007_30
Organisme : Thailand Science Research and Innovation Fund Chulalongkorn University
ID : HEA663000047
Informations de copyright
© 2024. The Author(s).
Références
Pramoolsinsap, C. Acute hepatitis A and acquired immunity to hepatitis A virus in hepatitis B virus (HBV) carriers and in HBV- or hepatitis C virus-related chronic liver diseases in Thailand. J. Viral Hepat.7(Suppl 1), 11–12. https://doi.org/10.1046/j.1365-2893.2000.00017.x (2000).
doi: 10.1046/j.1365-2893.2000.00017.x
pubmed: 10866839
Ruddy, S. J. et al. An epidemic of clam-associated hepatitis. JAMA208, 649–655 (1969).
doi: 10.1001/jama.1969.03160040057005
pubmed: 5818817
Keeffe, E. B. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases?. Am. J. Gastroenterol.90, 201–205 (1995).
pubmed: 7847285
Akriviadis, E. A. & Redeker, A. G. Fulminant hepatitis A in intravenous drug users with chronic liver disease. Ann. Intern. Med.110, 838–839. https://doi.org/10.7326/0003-4819-110-10-838 (1989).
doi: 10.7326/0003-4819-110-10-838
pubmed: 2712463
Danzinger-Isakov, L. & Kumar, D. A. S. T. Guidelines for vaccination of solid organ transplant candidates and recipients. Am. J. Transplant9(4), 258–262. https://doi.org/10.1111/j.1600-6143.2009.02917.x (2009).
doi: 10.1111/j.1600-6143.2009.02917.x
Danziger-Isakov, L., Kumar, D. & AST ID Community of practice,. Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice. Clin. Transplant.33(9), e13563. https://doi.org/10.1111/ctr.13563 (2019).
doi: 10.1111/ctr.13563
pubmed: 31002409
Madan, R. P. et al. A prospective, comparative study of the immune response to inactivated influenza vaccine in pediatric liver transplant recipients and their healthy siblings. Clin. Infect. Dis.46, 712–718. https://doi.org/10.1086/527391 (2008).
doi: 10.1086/527391
pubmed: 18230041
Verma, A. & Wade, J. J. Immunization issues before and after solid organ transplantation in children. Pediatr. Transplant10, 536–548. https://doi.org/10.1111/j.1399-3046.2006.00527.x (2006).
doi: 10.1111/j.1399-3046.2006.00527.x
pubmed: 16856989
Burroughs, M. & Moscona, A. Immunization of pediatric solid organ transplant candidates and recipients. Clin. Infect. Dis.30, 857–869. https://doi.org/10.1086/313823 (2000).
doi: 10.1086/313823
pubmed: 10852737
Sintusek, P. & Poovorawan, Y. Immunization status and hospitalization for vaccine-preventable and non-vaccine-preventable infections in liver-transplanted children. World J. Hepatol.13, 120–131. https://doi.org/10.4254/wjh.v13.i1.120 (2021).
doi: 10.4254/wjh.v13.i1.120
pubmed: 33584991
pmcid: 7856870
Sintusek, P. et al. High prevalence of hepatitis B-antibody loss and a case report of de novo hepatitis B virus infection in a child after living-donor liver transplantation. World J. Gastroenterol.24, 752–762. https://doi.org/10.3748/wjg.v24.i6.752 (2018).
doi: 10.3748/wjg.v24.i6.752
pubmed: 29456414
pmcid: 5807678
Funaki, T. et al. Serostatus following polio-containing vaccination before and after liver transplantation. Pediatr. Transplant24, e13766. https://doi.org/10.1111/petr.13766 (2020).
doi: 10.1111/petr.13766
pubmed: 32558028
Funaki, T. et al. Serostatus following live attenuated vaccination administered before pediatric liver transplantation. Liver Transpl.21, 774–783. https://doi.org/10.1002/lt.24104 (2015).
doi: 10.1002/lt.24104
pubmed: 25762489
Leung, D. H., Ton-That, M., Economides, J. M. & Healy, C. M. High prevalence of hepatitis B nonimmunity in vaccinated pediatric liver transplant recipients. Am. J. Transplant15, 535–540. https://doi.org/10.1111/ajt.12987 (2015).
doi: 10.1111/ajt.12987
pubmed: 25611886
Sintusek, P. et al. Safety and immunogenicity of standard and double doses of hepatitis b vaccine in children after liver transplantation: an open-label, Randomised Controlled Trial. Vaccines (Basel) https://doi.org/10.3390/vaccines10010092 (2022).
doi: 10.3390/vaccines10010092
pubmed: 36016212
Sintusek, P. et al. Safety and humoral and cellular immunogenicity of the BNT162b2 SARS-CoV-2 vaccine in liver-transplanted adolescents compared to healthy adolescents. Vaccines (Basel) https://doi.org/10.3390/vaccines10081324 (2022).
doi: 10.3390/vaccines10081324
pubmed: 36016212
de St Maurice, A. et al. High prevalence of hepatitis A and B nonimmunity in pediatric liver transplant recipients. Clin. Transplant37, e15035. https://doi.org/10.1111/ctr.15035 (2023).
doi: 10.1111/ctr.15035
pubmed: 37265180
Sa-nguanmoo, P. et al. Declining trend of hepatitis A seroepidemiology in association with improved public health and economic status of Thailand. PLoS One11, e0151304. https://doi.org/10.1371/journal.pone.0151304 (2016).
doi: 10.1371/journal.pone.0151304
pubmed: 27008531
pmcid: 4805277
Diana, A., Posfay-Barbe, K. M., Belli, D. C. & Siegrist, C. A. Vaccine-induced immunity in children after orthotopic liver transplantation: A 12-yr review of the Swiss national reference center. Pediatr. Transplant11, 31–37. https://doi.org/10.1111/j.1399-3046.2006.00596.x (2007).
doi: 10.1111/j.1399-3046.2006.00596.x
pubmed: 17239121
Feldman, A. G., Kempe, A., Beaty, B. L., Sundaram, S. S. & Studies of Pediatric Liver Transplantation Research, G. Immunization practices among pediatric transplant hepatologists. Pediatr Transplant20, 1038–1044 (2016). https://doi.org/10.1111/petr.12765
Dumot, J. A. et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. Am. J. Gastroenterol.94, 1601–1604. https://doi.org/10.1111/j.1572-0241.1999.01150.x (1999).
doi: 10.1111/j.1572-0241.1999.01150.x
pubmed: 10364031
Gunther, M. et al. Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients. Transplantation71, 477–479. https://doi.org/10.1097/00007890-200102150-00023 (2001).
doi: 10.1097/00007890-200102150-00023
pubmed: 11233913
Arslan, M., Wiesner, R. H., Poterucha, J. J. & Zein, N. N. Safety and efficacy of hepatitis A vaccination in liver transplantation recipients. Transplantation72, 272–276. https://doi.org/10.1097/00007890-200107270-00019 (2001).
doi: 10.1097/00007890-200107270-00019
pubmed: 11477352
Ferreira, C. T., da Silveira, T. R., Vieira, S. M., Taniguchi, A. & Pereira-Lima, J. Immunogenicity and safety of hepatitis A vaccine in children with chronic liver disease. J. Pediatr. Gastroenterol. Nutr.37, 258–261. https://doi.org/10.1097/00005176-200309000-00011 (2003).
doi: 10.1097/00005176-200309000-00011
pubmed: 12960646
Theeten, H. et al. Long-term antibody persistence after vaccination with a 2-dose Havrix (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions. Vaccine33, 5723–5727. https://doi.org/10.1016/j.vaccine.2015.07.008 (2015).
doi: 10.1016/j.vaccine.2015.07.008
pubmed: 26190091
Garcia Garrido, H. M. et al. Hepatitis A vaccine immunogenicity in patients using immunosuppressive drugs: A systematic review and meta-analysis. Travel Med. Infect. Dis.32, 101479. https://doi.org/10.1016/j.tmaid.2019.101479 (2019).
doi: 10.1016/j.tmaid.2019.101479
pubmed: 31521804
Arslan, M., Wiesner, R. H., Poterucha, J. J., Gross, J. B. Jr. & Zein, N. N. Hepatitis A antibodies in liver transplant recipients: Evidence for loss of immunity posttransplantation. Liver Transpl.6, 191–195. https://doi.org/10.1002/lt.500060216 (2000).
doi: 10.1002/lt.500060216
pubmed: 10719019
Zhu, J. et al. In-hospital post-transplant acute hepatitis A viral (HAV) infection in a liver transplant recipient who was HAV seropositive pre-transplant. Saudi J. Gastroenterol.25, 67–70. https://doi.org/10.4103/sjg.SJG_230_18 (2019).
doi: 10.4103/sjg.SJG_230_18
pubmed: 30117491
pmcid: 6373217
Sintusek, P. et al. Antibody persistence of standard versus double three-dose hepatitis B vaccine in liver transplant children: A randomized controlled trial. Sci. Rep.14, 499. https://doi.org/10.1038/s41598-024-51149-w (2024).
doi: 10.1038/s41598-024-51149-w
pubmed: 38177354
pmcid: 10767042